New insights on fumaric acid esters (Fumaderm®): Results of an experts' workshop;Neue Erkenntnisse zu Fumarsäureestern (Fumaderm ®): Ergebnisse eines Experten-Workshops

JDDG - Journal of the German Society of Dermatology

Volumn 9, Issue SUPPL. 4, 2011, Pages 1-13

  Mrowietz, Ulrich ^a   Adamczyk, A ^b   Augustin, M ^b   Boehncke, W H ^b   Bonnekoh, B ^b   Gambichler, T ^b   Hengge, U ^b   Lippert, U ^b   Ludwig, R J ^b   Luger, T ^b   Merk, H F ^b   Norgauer, J ^b   Philipp, S ^b   Reich, K ^b   Rocken M ^b   Rostami Yazdi, M ^b   Schon M P ^b   Scola, N ^b   Sticherling, M ^b   Thaci, D ^b   Viehweg, A ^b   Wallbrecht, K ^b   Wozel, G ^b   Zouboulis, C C ^b   Neureither, M ^b   more..

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FUMADERM;

CONFERENCE PAPER; HUMAN; WORKSHOP;

ADMINISTRATION, ORAL; ALOPECIA AREATA; AUTOIMMUNE DISEASES; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EDUCATION; FOLLOW-UP STUDIES; FUMARATES; HUMANS; IMMUNOGLOBULIN G; METABOLIC CLEARANCE RATE; PILOT PROJECTS; PROSPECTIVE STUDIES; PSORIASIS; PUVA THERAPY; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; SICK ROLE;

EID: 80052668818     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0379.2011.07765.x     Document Type: Conference Paper

References (74)

1. Schäfer I, Rustenbach SJ, Zimmer L, Augustin M. Prevalence of skin diseases in a cohort of 48,665 employees in Germany. Dermatology 2008; 217(2): 169-72.
2. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Comorbidity and age-related prevalence of psoriasis-analysis of health insurance data in Germany. Acta Derm Venereol 2010; 90: 147-51.
3. Nast A, Boehncke HW, Mrowietz U, Ockenfels HM, Philipp S, Reich K et al. S3-Leitlinie zur Therapie der Psoriasis vulgaris [online]. 2011 [cited 2011 Jun 02]; [199 screens]. Available from: URL: http://www.awmf.org/uploads/tx- szleitlinien/013-001l-S3-Psoriasis- vulgaris-Therapie-01.pdf
4. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, Franke J, Antoniou C, Arenberger P, Balieva F, Bylaite M, Correia O, Daudén E, Gisondi P, Iversen L, Kemény L, Lahfa M, Nijsten T, Rantanen T, Reich A, Rosenbach T, Segaert S, Smith C, Talme T, Volc-Platzer B, Yawalkar N. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res 2011; 303(1): 1-10.
5. Kimball A, Gieler U, Linder D, Sampogna F, Warren R, Augustin M. Psoriasis: is the impairment to a patient's life cumulative? J Eur Acad Dermatol Venereol 2010; 24(9), 989-1004.
6. Augustin M, Reich K, Blome C, Schäfer I, Laass A, Radtke M. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 2010; 163: 580-5.
7. Blome C, Simianer S, Purwins S, Laass A, Rustenbach SJ, Schaefer I, Radtke M, Augustin M. Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology 2010; 221(2), 154-9.
8. Radtke MA, Reich K, Blome C, Kopp I, Rustenbach SJ, Schäfer I, Augustin M. Evaluation of quality of care and guideline-compliant treatment in psoriasis: development of a new system of quality indicators. Dermatology 2009; 219(1): 54-8.
9. Schäfer I, Hacker J, Rustenbach SJ, Radtke M, Franzke N, Augustin M. Concordance of the Psoriasis Area and Severity Index (PASI) and patientreported outcomes in psoriasis treatment. Eur J Dermatol 2010; 20(1): 62-7.
10. Berger K, Ehlken B, Kugland B, Augustin M. Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2005; 3(7): 511-8. (Pubitemid 40942633)
11. Sohn S, Schöffski O, Prinz J, Reich K, Schubert E, Waldorf K, Augustin M. Cost of moderate to severe plaque psoriasis in Germany: a multicenter costof-illness study. Dermatology 2006; 212: 137-44.
12. Schöffski O, Augustin M, Prinz J, Rauner K, Schubert E, Sohn S, Reich K. Krankheitskosten und Lebensqualität bei Patienten mit mittelschwerer bis schwerer bis schwerer Psoriasis vulgaris in Deutschland: Eine multizentrische Studie. J Dtsch Dermatol Ges 2007; 5(3): 209-18.
13. Reich K, Krüger K, Mössner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol 2009; 160(5): 1040-7.
14. Augustin M, Glaeske G, Radtke M, Christophers E, Reich K, Schäfer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162(3): 633-6.
15. Gelfand J, Troxel A, Lewis J, Kurd S, Shin D, Wang X et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143(12): 1493-9. (Pubitemid 350277763)
16. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K: Disease Severity, Quality of Life and Health Care in Plaque-Type Psoriasis: A Multicenter Prospective Cross-Sectional Study in Germany. Dermatology 2008; 216: 366-372.
17. Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci 2010; 7(5): 284-9.
18. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, Gottlieb AB, Koo JY, Lebwohl M, Lim HW, Van Voorhees AS, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatology 2009; 61(3): 451-85.
19. Pietrzak A, Michalak-Stoma A, Chodorowska G, Szepietowski JC. Lipid disturbances in psoriasis: an update. Mediators Inflamm 2010; 2010. pii: 535612.
20. Mrowietz U, Rostami-Yazdi R, Neureither M, Reich K. 15 Jahre Fumaderm®: Fumarsäureester für die systemische Behandlung der mittelschweren bis schweren Psoriasis vulgaris. J Dtsch Dermatol Ges 2009; Suppl 2(7): S3-S16.
21. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, Barker J, Bos JD, Burmester GR, Chimenti S, Dubertret L, Eberlein B, Erdmann R, Ferguson J, Girolomoni G, Gisondi P, Giunta A, Griffiths C, Hönigsmann H, Hussain M, Jobling R, Karvonen SL, Kemeny L, Kopp I, Leonardi C, Maccarone M, Menter A, Mrowietz U, Naldi L, Nijsten T, Ortonne JP, Orzechowski HD, Rantanen T, Reich K, Reytan N, Richards H, Thio HB, van de Kerkhof P, Rzany B. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23(Suppl 2): 1-70.
22. Augustin M, Reich K, Reich C, Purwins S, Rustenbach SJ, Schäfer I, Radtke M. Versorgungsqualität der Psoriasis vulgaris in Deutschland-Ergebnisse der Nationale Versorgungsstudie PsoHealth 2007. J Dtsch Dermatol Ges 2008; 6(8): 640-6.
23. Augustin M, Schafer I, Reich K, Glaeske G, Radtke M. Systemic treatment with corticosteroids in psoriasishealth care provision far beyond the S3-guidelines, J Dtsch Dermatol Ges [serial online]. 2011 May 31 [cited 2011 June 17]; Available from: URL:http://onlinelibrary.wiley.com/doi/10.1111/j.1610- 0387.2011.07713.x/full.
24. Schöpf E, Augustin M. Therapie der Psoriasis mit Fumarsäure-Estern. Dtsch Arztebl 1996; 93(48): A3182-4.
25. Nast A, Spuls PH, Ormerod AD, Reytan N, Saiag PH, Smith CH, Rzany B. A critical appraisal of evidence-based guidelines for the treatment of psoriasis vulgaris: 'AGREE-ing' on a common base for European evidence-based psoriasis treatment guidelines. J Eur Acad Dermatol Venereol 2009; 23(7): 782-7.
26. Altmeyer P, Sterry W. Vorwort [editorial]. J Dtsch Dermatol Ges 2009; Suppl 2 (7): S1.
27. Mrowietz U. Vorwort. Expertenworkshop Fumaderm; 2010 Sep 22; Frankfurt/Main, Germany (unpublished).
28. Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T. Efficacy and safety of fumaric acid esters in the longterm treatment of psoriasis-a retrospective study (FUTURE). J Dtsch Dermatol Ges 2009; 7(7): 603-11.
29. Augustin M. Bericht: Kooperationsprojekte Biogen/CVderm. Expertenworkshop Fumaderm; 2010 Sep 22; Frankfurt/Main, Germany (unpublished).
30. Nationales Psoriasis-Register PsoBest. Stand 22. Februar 2011. Available from: URL:http://www.psobest.de/
31. Norgauer J. Psoriasis: Frühveränderungen an Gelenken. Möglichkeiten der Sonographie bei Diagnose und Verlaufskontrolle. Expertenworkshop Fumaderm; 2010 Sep 22; Frankfurt/Main, Germany (unpublished).
32. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-alpha-and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111(6): 821-31. (Pubitemid 37074957)
33. Witte E, Witte K, Warszawska K, Sabat R, Wolk K. Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev 2010; 21(5): 365-79.
34. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity 2004; 21(2): 241-54. (Pubitemid 39094053)
35. Wolk K, Haugen HS, Xu W, Witte E, Waggie K, Anderson M, Vom Baur E, Witte K, Warszawska K, Philipp S, Johnson-Leger C, Volk HD, Sterry W, Sabat R. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFNgamma are not. J Mol Med 2009; 87(5): 523-36.
36. Wolk K, Witte E, Warszawska K, Schulze-Tanzil G, Witte K, Philipp S, Kunz S, Döcke WD, Asadullah K, Volk HD, Sterry W, Sabat R. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur J Immunol 2009; 39(12): 3570-81.
37. Sabat R, Philipp S, Höflich C, Kreutzer S, Wallace E, Asadullah K, Volk HD, Sterry W, Wolk K. Immunopathogenesis of psoriasis. Exp Dermatol 2007; 16: 779-98.
38. Philipp S, Sabat R. Immunparameter: Fumaderm und IL-22. Expertenworkshop Fumaderm; 2010 Sep 22; Frankfurt/Main, Germany (unpublished).
39. Kahl C, Neureither M, Reich K, Zschocke I. Zeitmanagement und Lebensqualitat nach Umstellung einer topischen und/oder Fototherapie auf Fumarsäreester bei Patienten mit Psoriasis. Akt Dermatol 2011; 37: 249-253.
40. Sticherling M. Psoriasis beim Mann: Systemische Therapie und Spermiogenese. Expertenworkshop Fumaderm; 2010 Sep 22; Frankfurt/Main, Germany (unpublished).
41. Wozel G, Viehweg A. Kombination von UV-Bestrahlung und Fumarsäureester. Expertenworkshop Fumaderm; 2010 Sep 22; Frankfurt/Main, Germany (unpublished).
42. Thaci D. Therapietreue-wichtig für den Therapieerfolg? Zwischenauswertung einer laufenden nicht-interventionellen Studie. Expertenworkshop Fumaderm; 2010 Sep 22; Frankfurt/Main, Germany (unpublished).
43. Hengge U. Genotyping. Expertenworkshop Fumaderm; 2010 Sep 22; Frankfurt/Main, Germany (unpublished).
44. Mirmohammadsadegh A, Tschakarjan E, Ljoljic A, Bohner K, Michel G, Ruzicka T, Goos M, Hengge UR. Calgranulin C is overexpressed in lesional psoriasis. J Invest Dermatol 2000; 114(6): 1207-8.
45. Bonnekoh B. Topoproteom-Analyse der Psoriasis unter Fumarat-Behandlung (ToPoF-Studie). Expertenworkshop Fumaderm; 2010 Sep 22; Frankfurt/Main, Germany (unpublished).
46. Sebök B, Mahrle G, Gollnick H, Bonnekoh B. Dimethylfumarat ist unter den Fumaderm®-Inhaltsstoffen der stärkste Induktor von Apoptose-Phänomenen in lympho-histiozytären U-937-Zellen. Z Hautkr 2000; 75: 1-5.
47. Sebök B, Bonnekoh B, Mahrle G. IL-1 alpha-induced expression of ICAM-1 on cultured hyperproliferative keratinocytes: suppression by antipsoriatic dimethyl-fumarate. Int J Dermatol 1994 May; 33(5): 367-70.
48. Sebök B, Bonnekoh B, Geisel J, Mahrle G. Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivatives in keratinocyte cultures. Eur J Pharmacol 1994; 270(1): 79-87.
49. Scola N, Müller M, Altmeyer P, Gambichler T. Glutathion S-Transferase T1 Aktivität und Psoriasis-Therapie mit FAE. Expertenworkshop Fumaderm; 2010 Sep 22; Frankfurt/Main, Germany (unpublished).
50. Spencer SR, Wilczak CA, Talalay P. Induction of glutathione transferases and NAD(P)H:quinone reductase by fumaric acid derivatives in rodent cells and tissues. Cancer Res. 1990; 50(24): 7871-5.
51. Anderson KS, Wong J, Polyak K, Aronzon D, Enerbäck C. Detection of psoriasin/S100A7 in the sera of patients with psoriasis. Br J Dermatol 2009; 160(2): 325-32.
52. Jansen PA, Rodijk-Olthuis D, Hollox EJ, Kamsteeg M, Tjabringa GS, de Jongh GJ, van Vlijmen-Willems IM, Bergboer JG, van Rossum MM, de Jong EM, den Heijer M, Evers AW, Bergers M, Armour JA, Zeeuwen PL, Schalkwijk J. Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. PLoS One 2009; 4(3): e4725.
53. Merk H. Wirkung auf dendritische Zellen. Expertenworkshop Fumaderm; 2010 Sep 22; Frankfurt/Main, Germany (unpublished).
54. Mrowietz U, Rostami-Yazdi R. Psoriasis und Fumaderm®-Neue wissenschaftliche Erkenntnisse Pharmakokinetik und Wirkmechanismus von Fumarsäureestern. Expertenworkshop Fumaderm; 2010 Sep 22; Frankfurt/Main, Germany (unpublished).
55. Rostami-Yazdi M, Clement B, Schmidt TJ, Schinor D, Mrowietz U. Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. J Invest Dermatol 2009; 129(1): 231-4.
56. Schön MP, Wallbrecht K. Fumarsäureester: Wirkung auf Endothelzellen und Lymphozyteninteraktion. Expertenworkshop Fumaderm; 2010 Sep 22; Frankfurt/Main, Germany (unpublished).
57. Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A, Figueiredo A, Teixeira F, Castro E, Rocha-Pereira P, Santos-Silva A. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol 2010; 24(7): 789-96.
58. Garbaraviciene J, Diehl S, Varwig D, Bylaite M, Ackermann H, Ludwig RJ, Boehncke WH. Platelet P-selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis. Exp Dermatol 2010; 19: 736-41.
59. Boehncke WH, Boehncke S, Schoen MP. Managing comorbid disease in patients with psoriasis. BMJ 2010; 340: b5666.
60. Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, Badenhoop K, Boehncke WH. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007; 157: 1249-51. (Pubitemid 350115673)
61. Boehncke WH, Boehncke S, Tobin AM, Kirby B. The "psoriatic march": a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011; 20(4): 303-7.
62. Boehncke S, Salgo R, Garbaraviciene J, Beschmann H, Hardt K, Diehl S, Fichtlscherer S, Thaçi D, Boehncke WH. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 2011 [Epub ahead of print].
63. Salgo R, Thaci D, Boehncke S, Diehl S, Hofmann M, Boehncke WH. Microdialysis documents changes in the micromilieu of psoriatic plaques under continuous systemic therapy. Exp Dermatol 2011, 20: 130-3.
64. Boehncke S, Fichtlscherer S, Salgo R, Garbaraviciene J, Beschmann H, Diehl S, Hardt K, Thaçi D, Boehncke WH. Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. Arch Dermatol Res 2010 [Epub ahead of print].
65. Dempsey OJ, Paterson EW, Kerr KM, Denison AR. Sarcoidosis. Br Med J 2009; 339: b3206.
66. Stridh H, Planck A, Gigliotti D, Eklund A, Grunewald J. Apoptosis resistant bronchoalveolar lavage (BAL) fluid lymphocytes in sarcoidosis. Thorax 2002; 57: 897-901. (Pubitemid 35178616)
67. Lippert U, Zouboulis CC. Sarkoidose und Fumarsäureester. Expertenworkshop Fumaderm; 2010 Sep 22; Frankfurt/Main, Germany (unpublished).
68. Röcken M, Adamcyk A. Behandlung von Alopecia areata mit Fumaraten. Expertenworkshop Fumaderm; 2010 Sep 22; Frankfurt/Main, Germany (unpublished).
69. Chiriac MT, Roesler J, Sindrilaru A, Scharffetter-Kochanek K, Zillikens D, Sitaru C. NADPH oxidase is required for neutrophil-dependent autoantibody-induced tissue damage. J Pathol 2007; 212(1): 56-65. (Pubitemid 46746290)
70. Yu X, Holdorf K, Kasper B, Zillikens D, Ludwig RJ, Petersen F. FcγRIIA and FcγRIIIB are required for autoantibody-induced tissue damage in experimental human models of bullous pemphigoid. J Invest Dermatol 2010; 130(12): 2841-4.
71. Recke A, Sitaru C, Vidarsson G, Evensen M, Chiriac MT, Ludwig RJ, Zillikens D. Pathogenicity of IgG subclass autoantibodies to type VII collagen: induction of dermal-epidermal separation. J Autoimmun 2010; 34(4): 435-44.
72. Kasperkiewicz M, Müller R, Manz R, Magens M, Hammers CM, Somlai C, Westermann J, Schmidt E, Zillikens D, Ludwig RJ, Orosz A. Heat shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that non-malignant plasma cells are not therapeutic targets. Blood 2011; 117(23): 6135-42.
73. Luger TA, Kuhn A. Kutaner Lupus Erythematodes. Expertenworkshop Fumaderm; 2010 Sep 22; Frankfurt/Main, Germany (unpublished).
74. Wallbrecht K, Drick N, Schön MP. Downregulation of endothelial adhesion molecules by dimethylfumarate, but not monomethylfumarate, and impairment of dynamic lymphocyte-endothelial cell interactions. 2011. In revision.